Automation in clinical trials: Why it’s essential for success
Many companies in the life sciences industry are slow to adopt new technologies. This is…
CertaraAugust 19, 2024
Subject Exposure in Aggregate Safety Reports & Common Issues
All new and existing drugs should be safe, effective, and efficacious for the treated populations.…
CertaraAugust 16, 2024
Certara Launches Phoenix™ Version 8.5 Drug Development Software
RADNOR, PA – August 15, 2024 - Certara, Inc. (Nasdaq: CERT), a global leader in…
CertaraAugust 15, 2024
Certara Research Reveals IRA’s Impact on Biosimilar Uptake
RADNOR, PA - August 15, 2024 -- Certara, Inc., a global leader in model-informed drug…
CertaraAugust 15, 2024
Mastering Value Storytelling in Healthcare: Leveraging Digital Tools to Meet Stakeholders’ Expectations
Everyone loves a good story. Stories are more likely to move and engage people than…
CertaraAugust 14, 2024
Evaluating the IRA’s Impact on Medicare Part B Biosimilar Reimbursement
White paper exploring the IRA’s small but measurable impact in several key areas
CertaraAugust 13, 2024
All you need to know about NCI, CDISC and SDTM controlled terminology
The use of controlled terminology (CT) is vital to successful clinical study build. In clinical…
CertaraAugust 13, 2024
Digital Payer Portals for Enhanced Value Communication
The trend of using digital tools for communication and information sharing in the life science…
CertaraAugust 9, 2024
Certara’s MIDD Oncology Capabilities
Improve Oncology Study Decisions with Certara's MIDD Team Transcript: The pace of oncology drug…
CertaraAugust 7, 2024
